Japan's Mochida Pharma To Expand Generic, Biosimilar Cancer Business
This article was originally published in PharmAsia News
Executive Summary
Mochida Pharmaceutical plans to expand its generics and biosimilars lines with an eye on building a $110.2 million-a-year business over the next three years, a rate double this year's expected earnings.
You may also be interested in...
Cybersecurity: Guidance Docs To Come, But Legacy Devices Still A Challenge
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
Majority Of Spanish OTC Firms Investing Heavily In Digital
A recent ANEFP survey shows that the majority of Spanish OTC firms consider their digital strategies to be "very advanced."
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports